Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Cone Beam CT for Breast Imaging

18 juni 2013 uppdaterad av: Koning Corporation

Cone Beam CT for Breast Imaging: A Pilot Study

The objective of this pilot study is to investigate Cone Beam Computed Tomography Imaging (CBCT), with the primary goal, the accumulation of a body of evidence to provide preliminary data for a future extensive clinical trials.

Studieöversikt

Status

Avslutad

Studietyp

Observationell

Inskrivning (Faktisk)

76

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • New York
      • Rochester, New York, Förenta staterna, 14620
        • University of Rochester Highland Breast Imaging Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

40 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Kvinna

Testmetod

Icke-sannolikhetsprov

Studera befolkning

In Group I, up to 100 women, at least 40 years of age, who have had a routine standard mammogram read as BI-RADS® 0, 1, 2, or 3 will also undergo 3D breast imaging using a cone beam CT scanner specifically designed to image the breast.

Group II includes forty (40) women, who have had abnormalities detected by physical exam or an imaging modality and are also scheduled for breast biopsy of the index lesion, will also undergo a CBCT of the breast(s), prior to biopsy.

Beskrivning

Normal Group:

Inclusion Criteria:

  • Are at least 40 years of age of any ethnicity
  • Had a routine mammogram, read as BI-RADS® 0, 1, 2 or 3
  • Will undergo study imaging no later than six months from date of routine mammogram.
  • Is able to undergo informed consent.

Exclusion Criteria:

  • Pregnancy
  • Lactation
  • Patients with physical limitations that may prohibit resting prone on the exam table, such as, but not limited to: frozen shoulder, recent heart surgery, pace maker.
  • Patients who are unable to tolerate study constraints.
  • Patients who have received radiation treatments to the thorax for malignant and nonmalignant conditions, such as (but not limited to)

    • Treatment for enlarged thymus gland as an infant
    • Irradiation for benign breast conditions, including breast inflammation after giving birth
    • Treatment for Hodgkin's disease
  • Patients who have participated in a prior breast clinical trial that gave additional radiation dose, such as an additional mammogram.
  • Patients who have received large numbers of diagnostic x-ray examinations for monitoring of disease such as (but not limited to)

    • Tuberculosis
    • Severe scoliosis

Diagnostic Group:

Inclusion Criteria:

  • Women who are at least 40 years of age of any ethnicity
  • Have a palpable abnormality detected by Breast Self Exam (BSE), or Clinical Breast Exam (CBE) or have a non-palpable abnormality detected by an imaging modality
  • After diagnostic work-up are categorized as BI-RADS® 4 or 5.
  • Are scheduled for biopsy either by large gauge needle biopsy or excisional biopsy.
  • Will undergo study imaging prior to biopsy and within four weeks of diagnostic work-up.

Exclusion Criteria:

  • Pregnancy
  • Lactation
  • Patients who have already undergone biopsy for the index lesion
  • Patients who are unable or unwilling to undergo biopsy for the lesion of concern
  • Patients with physical limitations that may prohibit the patient from resting prone on the exam table, such as, but not limited to: frozen shoulder, recent heart surgery, pace maker.
  • Patients who are unable to tolerate study constraints.
  • Patients who have received radiation treatments to the thorax or breast area for malignant and nonmalignant conditions, such as (but not limited to)

    • Treatment for enlarged thymus gland as an infant
    • Irradiation for benign breast conditions, including breast inflammation after giving birth
    • Treatment for Hodgkin's disease
  • Patients who have participated in a prior breast clinical trial that gave additional radiation dose, such as an additional mammogram.
  • Patients who have received large numbers of diagnostic x-ray examinations for monitoring of disease such as (but not limited to)

    • Tuberculosis
    • Severe scoliosis

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Normal Group
In Group I, up to 100 women, at least 40 years of age, who have had a routine standard mammogram read as BI-RADS® 0, 1, 2, or 3 will also undergo 3D breast imaging using a cone beam CT scanner specifically designed to image the breast. Of these 100, we hope to enroll at least 30 subjects with mammograms read as BI-RADS® 0 and at least 30 read as BI-RADS® 3. The BI-RADS® 0 category refers to patients for whom additional imaging is required after a screening mammogram provided incomplete diagnostic information.
Diagnostic Group
The goals of Group II will be to compare the CBCT study with standard imaging for the diagnosis of breast disease in palpable or non-palpable breast lesions (having a BI-RADS® score of 4 or 5). Forty (40) women, who have had abnormalities detected by physical exam or an imaging modality and are also scheduled for breast biopsy of the index lesion, will also undergo a CBCT of the breast(s), prior to biopsy.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Image Quality of Cone Beam Breast CT
Tidsram: 6 years
This study was to evaluate the radiation dose, breast coverage, and image quality of cone-beam breast CT compared with a conventional mammographic examination.
6 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Samarbetspartners

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 juli 2006

Primärt slutförande (Faktisk)

1 juni 2012

Avslutad studie (Faktisk)

1 juni 2012

Studieregistreringsdatum

Först inskickad

15 juni 2013

Först inskickad som uppfyllde QC-kriterierna

18 juni 2013

Första postat (Uppskatta)

19 juni 2013

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

19 juni 2013

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

18 juni 2013

Senast verifierad

1 juni 2013

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • URMC-001

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera